Here&#x27;s a figure from the article posted by Eric Topol on twitter: <a href="https:&#x2F;&#x2F;twitter.com&#x2F;EricTopol&#x2F;status&#x2F;729688822053670912" rel="nofollow">https:&#x2F;&#x2F;twitter.com&#x2F;EricTopol&#x2F;status&#x2F;729688822053670912</a><p>Combined with the stat you mentioned, it&#x27;s a strange one. Maybe I&#x27;m looking at it wrong, but there&#x27;s barely any physicians receiving above $50k in payments, so the biggest impact pharma payments have made is around a 5 % difference in prescribing. Looking at the variation at around $0-$10k, 5 % seems like a tiny change, since you have docs prescribing anywhere from 0 % and 80 %. Something else is driving it, my guess would be good personal relationships with sales reps? In that case, focusing on limiting that would have a much better impact on fixing the issue.<p>The big variation could also be something completely innocent like trust in a specific brand due to experience in the clinic, etc. Perhaps someone more knowledgeable can chime in.